


WHAT IS CLAIMED:

1. A compound of Formula (I):

5



(I)

wherein:

R¹ is selected from the group consisting of hydrogen, halo, alkyl, cycloalkyl, aryl, heteroaryl, heterocyclic, hydroxy, alkoxy, -(CO)R¹⁵, -NR¹³R¹⁴, -(CH₂)ₙR¹⁶ and -C(O)NR⁹R⁹;

R² is selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano, -NR¹³R¹⁴, -NR¹³C(O)R¹⁴, -C(O)R¹⁵, aryl, heteroaryl, and -S(O)₂NR¹³R¹⁴;

R³ is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy, -(CO)R¹⁵, -NR¹³R¹⁴, aryl, heteroaryl, -NR¹³S(O)₂R¹⁴, -S(O)₂NR¹³R¹⁴, -

NR¹³C(O)R¹⁴,
-NR¹³C(O)OR¹⁴ and -SO₂R²⁰ (wherein R²⁰ is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl);

R⁴ is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and -NR¹³R¹⁴;

R⁵ is selected from the group consisting of hydrogen, alkyl and -C(O)R¹⁰;

R⁶ is selected from the group consisting of hydrogen, alkyl and -C(O)R¹⁰;

R⁷ is selected from the group consisting of hydrogen,

alkyl, aryl, heteroaryl, $-C(O)R^{17}$ and $-C(O)R^{10}$; or
R⁶ and R⁷ may combine to form a group selected from the
group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$ and $-(CH_2)_6-$;
with the proviso that at least one of R⁵, R⁶ or R⁷ must be
5 $-C(O)R^{10}$;
R⁸ and R⁹ are independently selected from the group
consisting of hydrogen, alkyl and aryl;
R¹⁰ is selected from the group consisting of hydroxy,
alkoxy, aryloxy, $-N(R^{11})(CH_2)_nR^{12}$, and $-NR^{13}R^{14}$;
10 R¹¹ is selected from the group consisting of hydrogen and
alkyl;
R¹² is selected from the group consisting of $-NR^{13}R^{14}$,
hydroxy, $-C(O)R^{15}$, aryl, heteroaryl, $-N^+(O^-)R^{13}R^{14}$, $-N(OH)R^{13}$, and
-NHC(O)R^a (wherein R^a is unsubstituted alkyl, haloalkyl, or
15 aralkyl);
R¹³ and R¹⁴ are independently selected from the group
consisting of hydrogen, alkyl, lower alkyl substituted with
hydroxyalkylamino, cyanoalkyl, cycloalkyl, aryl and
heteroaryl; or
20 R¹³ and R¹⁴ may combine to form a heterocyclo group;
R¹⁵ is selected from the group consisting of hydrogen,
hydroxy, alkoxy and aryloxy;
R¹⁶ is selected from the group consisting of hydroxy,
-C(O)R¹⁵, $-NR^{13}R^{14}$ and $-C(O)NR^{13}R^{14}$;
25 R¹⁷ is selected from the group consisting of alkyl,
cycloalkyl, aryl and heteroaryl;
R²⁰ is alkyl, aryl, aralkyl or heteroaryl; and
n and r are independently 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.

30 2. The compound or salt of Claim 1 wherein:

R¹ is selected from the group consisting of hydrogen,
halo, alkyl, cycloalkyl, aryl, heteroaryl, heteroalicyclic,
35 hydroxy, alkoxy, $-C(O)R^{15}$, $-NR^{13}R^{14}$, $-(CH_2)_rR^{16}$ and $-C(O)NR^8R^9$;
R² is selected from the group consisting of hydrogen,
halo, alkyl, trihalomethyl, hydroxy, alkoxy, $-NR^{13}R^{14}$, -

$\text{NR}^{13}\text{C(O)R}^{14}$, $-\text{C(O)R}^{15}$, aryl, heteroaryl, and $-\text{S(O)}_2\text{NR}^{13}\text{R}^{14}$;

R^3 is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy, $-(\text{CO})\text{R}^{15}$, $-\text{NR}^{13}\text{R}^{14}$, aryl, heteroaryl, $-\text{NR}^{13}\text{S(O)}_2\text{R}^{14''}$ $-\text{S(O)}_2\text{NR}^{13}\text{R}^{14}$, -

5 $\text{NR}^{13}\text{C(O)R}^{14}$, and $-\text{NR}^{13}\text{C(O)OR}^{14}$;

R^4 is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and $-\text{NR}^{13}\text{R}^{14}$;

10 R^5 is selected from the group consisting of hydrogen, alkyl and $-\text{C(O)R}^{10}$;

R^6 is selected from the group consisting of hydrogen, alkyl and $-\text{C(O)R}^{10}$;

15 R^7 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, $-\text{C(O)R}^{17}$ and $-\text{C(O)R}^{10}$;

R^6 and R^7 may combine to form a group selected from the group consisting of $-(\text{CH}_2)_4-$, $-(\text{CH}_2)_5-$ and $-(\text{CH}_2)_6-$; with the proviso that at least one of R^5 , R^6 or R^7 must be $-\text{C(O)R}^{10}$;

20 R^8 and R^9 are independently selected from the group consisting of hydrogen, alkyl and aryl;

25 R^{10} is selected from the group consisting of hydroxy, alkoxy, aryloxy, $-\text{N}(\text{R}^{11})(\text{CH}_2)_n\text{R}^{12}$ and $-\text{NR}^{13}\text{R}^{14}$;

R^{11} is selected from the group consisting of hydrogen and alkyl;

30 R^{12} is selected from the group consisting of $-\text{NR}^{13}\text{R}^{14}$, hydroxy, $-\text{C(O)R}^{15}$, aryl and heteroaryl;

R^{13} and R^{14} are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl and heteroaryl;

35 R^{13} and R^{14} may combine to form a group selected from the group consisting of $-(\text{CH}_2)_4-$, $-(\text{CH}_2)_5-$, $-(\text{CH}_2)_2\text{O}(\text{CH}_2)_2-$, and $-(\text{CH}_2)_2\text{N}(\text{CH}_3)(\text{CH}_2)_2-$;

R^{15} is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

40 R^{16} is selected from the group consisting of hydroxy, $-\text{C(O)R}^{15}$, $-\text{NR}^{13}\text{R}^{14}$ and $-\text{C(O)NR}^{13}\text{R}^{14}$;

R^{17} is selected from the group consisting of alkyl,

cycloalkyl, aryl and heteroaryl; and
n and r are independently 1, 2, 3, or 4;
or a pharmaceutically acceptable salt thereof.

- 5 3. The compound or salt of Claim 1 wherein R⁵ is -COR¹⁰
wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:
R¹¹ is hydrogen or lower unsubstituted alkyl;
n is 2 or 3; and
R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently
10 unsubstituted lower alkyl.
4. The compound or salt of Claim 1 wherein R⁵ is -COR¹⁰
wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:
R¹¹ is hydrogen or lower unsubstituted alkyl;
n is 2 or 3; and
R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ combine to form a
group selected from -(CH₂)₄- , -(CH₂)₅- , -(CH₂)₂-O-(CH₂)₂- or
-(CH₂)₂N(CH₃)(CH₂)₂-.
- 15 5. The compound of Claim 1 wherein R⁵ is N-(2-dimethylamino-
ethyl)aminocarbonyl, N-(2-diethylaminoethyl)-N-methyl-
aminocarbonyl, N-(3-dimethylaminopropyl)aminocarbonyl, N-
(2-diethylaminoethyl)aminocarbonyl, N-(3-
ethylaminopropyl)-aminocarbonyl, N-(2-
25 ethylaminoethyl)aminocarbonyl, or N-(3-
diethylaminopropyl)aminocarbonyl.
6. The compound of Claim 1 wherein R⁵ is N-(2-diethyl-
aminoethyl)aminocarbonyl or N-(2-ethylaminoethyl)amino-
30 carbonyl.
7. The compound of Claim 1 wherein R⁵ is 3-pyrrolidin-1-
ylpropylaminocarbonyl, 3-morpholin-4-ylpropylamino-
carbonyl, 2-pyrrolidin-1-ylethylaminocarbonyl, 2-
35 morpholin-4-yl-ethylaminocarbonyl, 2-(4-methylpiperazin-
1-yl)ethyl-aminocarbonyl, 2-(3,5-dimethylpiperazin-1-

yl)ethyl-aminocarbonyl, 3-(4-methylpiperazin-1-yl)propylamino-carbonyl or 3-(3,5-dimethylpiperazin-1-yl)propylamino-carbonyl.

- 5 8. The compound or salt of Claim 1 wherein R⁶ is -COR¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:
R¹¹ is hydrogen or lower unsubstituted alkyl;
n is 2 or 3; and
R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ are independently
10 unsubstituted lower alkyl.
9. The compound or salt of Claim 1 wherein R⁶ is -COR¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:
R¹¹ is hydrogen or lower unsubstituted alkyl;
n is 2 or 3; and
R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ combine to form a group selected from -(CH₂)₄-¹⁵, -(CH₂)₅-¹⁶, -(CH₂)₂O-(CH₂)₂- or -(CH₂)₂N(CH₃)(CH₂)₂-¹⁷.
- 10 10. The compound or salt of Claim 1 wherein R⁶ is N-(2-dimethylamino-ethyl)aminocarbonyl, N-(2-diethylaminoethyl)-N-methylaminocarbonyl, N-(3-dimethylamino-propyl)-aminocarbonyl, N-(2-diethylaminoethyl)-aminocarbonyl, N-(2-ethylaminoethyl)-aminocarbonyl, N-(3-ethylaminopropyl)-aminocarbonyl, or N-(3-diethylamino-propyl)aminocarbonyl.
25
11. The compound or salt of Claim 1 wherein R⁶ is N-(2-diethylaminoethyl)aminocarbonyl or N-(2-ethylaminoethyl)aminocarbonyl.
30
12. The compound or salt of Claim 1 wherein R⁶ is 3-pyrrolidin-1-ylpropylaminocarbonyl, 3-morpholin-4-ylpropylamino-carbonyl, 2-pyrrolidin-1-ylethylaminocarbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl, 2-(3,5-
- 35

dimethylpiperazin-1-yl)ethyl-aminocarbonyl, 3-(4-methylpiperazin-1-yl)propylamino-carbonyl or 3-(3,5-dimethylpiperazin-1-yl)propylamino-carbonyl.

- 5 13. The compound or salt of Claim 1 wherein R⁵ is -COR¹⁰ wherein R¹⁰ is -NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is lower alkyl substituted with hydroxy, aryl, heteroalicyclic, heteroaryl, or carboxy.
- 10 14. The compound or salt of Claim 1 wherein R⁵ is 3-triazin-1-ylpropylaminocarbonyl, 2-triazin-1-ylethylaminocarbonyl, 3-imidazol-1-ylpropylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, 2-pyridin-2-ylethylaminocarbonyl or 2-imidazol-1-yl ethylaminocarbonyl.
- 15 15. The compound or salt of Claim 1 wherein R⁶ is -COR¹⁰ wherein R¹⁰ is -NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is lower alkyl substituted with hydroxy, aryl, heteroalicyclic, heteroaryl, or carboxy.
- 20 16. The compound or salt of Claim 1 wherein R⁶ is 2-triazin-1-ylpropylaminocarbonyl, 2-triazin-1-ylethylaminocarbonyl, 3-imidazol-1-ylpropylaminocarbonyl, pyridin-4-ylmethylaminocarbonyl, 2-pyridin-2-ylethylaminocarbonyl or 2-imidazol-1-yl ethylaminocarbonyl.
- 25 17. The compound or salt of Claim 1 wherein R⁵ is -COR¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:
R¹¹ is hydrogen or lower unsubstituted alkyl;
n is 2 or 3; and
R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ together combine to form a heterocycle.
- 30 18. The compound or salt of Claim 1 wherein R⁵ is -COR¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:
R¹¹ is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ together combine to form a 5, 6 or 7 atom heterocycle containing a carbonyl group and one or two nitrogen atoms within the ring.

5

19. The compound or salt of Claim 1 wherein R⁵ is 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)-

10

ethylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propyl-aminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-aminocarbonyl, 3-(tetrahydropyrimidin-1-yl-2-one)-propylaminocarbonyl, or 3-(2-oxopyrrolidin-1-yl)propyl-aminocarbonyl.

15
16
17
18
19
20

20. The compound or salt of Claim 1 wherein R⁶ is -COR¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:

R¹¹ is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ together combine to form a heterocycle.

25
26
27
28
29

21. The compound or salt of Claim 1 wherein R⁶ is -COR¹⁰ wherein R¹⁰ is -NR¹¹(CH₂)_nR¹² wherein:

R¹¹ is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

R¹² is -NR¹³R¹⁴ wherein R¹³ and R¹⁴ together combine to form a 5, 6 or 7 atom heterocycle containing a carbonyl group and one or two nitrogen atoms within the ring.

30

22. The compound or salt of Claim 1 wherein R⁶ is 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)-ethylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propyl-aminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-

35

S(O)₂NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is hydrogen, aryl or alkyl; R³ is selected from the group consisting of hydrogen, lower alkoxy, -C(O)R¹⁵, -NR¹³C(O)R¹⁴, aryl optionally substituted with one or two substitutents selected from the group consisting of lower alkyl, halo, or lower alkoxy, and heteroaryl; and
5 R⁴ is hydrogen.

28. The compound or salt of Claim 23 wherein:

10 R¹ is hydrogen or phenyl;

R² is hydrogen, chloro, bromo, fluoro, methoxy, ethoxy, phenyl, cyano, dimethylaminosulfonyl, 3-chlorophenyl-aminosulfonyl, carboxy, methoxy, aminosulfonyl, methylaminosulfonyl, methylsulfonyl ethylsulfonyl, benzylsulfonyl, phenylaminosulfonyl, pyridin-3-yl-aminosulfonyl, dimethylaminosulfonyl, or isopropylamino-sulfonyl;

15 R³ is hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl, 3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl, or 3-isopropylphenyl; and

20 R⁴ is hydrogen.

29. The compound or salt of Claim 23 wherein:

25 R¹ is hydrogen;

R² is hydrogen, cyano, fluoro, chloro, or bromo;

R³ is hydrogen; and

R⁴ is hydrogen.

30. The compound or salt of Claim 25 wherein:

35 R¹ is hydrogen, unsubstituted lower alkyl, -C(O)NR⁸R⁹, unsubstituted cycloalkyl or aryl;

R² is hydrogen, halo, lower alkoxy, cyano, aryl, -SO₂R20, or -S(O)₂NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is hydrogen, aryl or alkyl;

R³ is selected from the group consisting of hydrogen, lower alkoxy, -C(O)R¹⁵, -NR¹³C(O)R¹⁴, aryl and heteroaryl;

and

R⁴ is hydrogen.

31. The compound or salt of Claim 25 wherein:

R¹ is hydrogen or phenyl;

R² is hydrogen, chloro, bromo, fluoro, methoxy, ethoxy, phenyl, dimethylaminosulfonyl, cyano, methylsulfonyl, ethylsulfonyl, benzylsulfonyl, 3-chlorophenyl-aminosulfonyl, carboxy, methoxy, aminosulfonyl, methylaminosulfonyl, phenylaminosulfonyl, pyridin-3-yl-aminosulfonyl, dimethylaminosulfonyl, or isopropylamino-sulfonyl;

R³ is hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl, 3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl, 3-isopropylphenyl; and

R⁴ is hydrogen.

32. The compound or salt of Claim 25 wherein:

R¹ is hydrogen;

R² is hydrogen, cyano, fluoro, chloro, or bromo;

R³ is phenyl; and

R⁴ is hydrogen.

33. The compound or salt of Claim 1 wherein:

R¹ is hydrogen, unsubstituted lower alkyl, -C(O)NR⁸R⁹, unsubstituted cycloalkyl or aryl;

R² is hydrogen, halo, lower alkoxy, cyano, aryl or -S(O)₂NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is hydrogen, aryl or alkyl; R³ is selected from the group consisting of hydrogen, lower alkoxy, -C(O)R¹⁵, -NR¹³C(O)R¹⁴, aryl, and heteroaryl; and

R⁴ is hydrogen.

34. The compound or salt of Claim 1 wherein:

R¹ is hydrogen, or methyl;

R² is hydrogen, cyano, chloro, fluoro, or bromo;

R³ is selected from the group consisting of hydrogen or phenyl; and
R⁴ is hydrogen.

- 5 35. The compound or salt of Claim 33 or 34 wherein:

R⁵ is -COR¹⁰;

R⁶ is selected from the group consisting of hydrogen and unsubstituted lower alkyl; and

10 R⁷ is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and -C(O)R¹⁷ wherein R¹⁷ is hydroxy, unsubstituted lower alkyl or aryl.

36. The compound or salt of Claim 33 or 34 wherein:

R⁶ is -COR¹⁰;

15 R⁵ is selected from the group consisting of hydrogen and unsubstituted lower alkyl; and

R⁷ is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and -C(O)R¹⁷ wherein R¹⁷ is hydroxy, unsubstituted lower alkyl or aryl.

37. The compound or salt of Claim 1 wherein R⁵ is -COR¹⁰

20 wherein R¹⁰ is -NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is lower alkyl substituted with hydroxy, lower alkyl substituted with hydroxyalkylamino, carboxy, or -NR¹⁸R¹⁹ wherein R¹⁸ and R¹⁹ are independently hydrogen or lower unsubstituted alkyl.

38. The compound or salt of Claim 1 wherein R⁵ is 2-

25 [(diethylamino)-2-hydroxyethyl]aminocarbonyl, 2-(N-ethyl-N-2-hydroxyethylamino)ethylaminocarbonyl, carboxymethylamino-carbonyl, or 2-hydroxyethylamino-carbonyl.

39. The compound or salt of Claim 1 wherein R⁶ is -COR¹⁰

35 wherein R¹⁰ is -NR¹³R¹⁴ wherein R¹³ is hydrogen and R¹⁴ is lower alkyl substituted with hydroxy, lower alkyl

substituted with hydroxyalkylamino, carboxy, or $-NR^{18}R^{19}$ wherein R^{18} and R^{19} are independently hydrogen or lower unsubstituted alkyl.

- 5 40. The compound or salt of Claim 1 wherein R^6 is [2-(diethylamino)-2-hydroxy]ethylaminocarbonyl, 2-(N-ethyl-N-2-hydroxyethylamino)ethylaminocarbonyl, carboxymethylaminocarbonyl, or 2-hydroxyethylaminocarbonyl.

10

41. The compound of Claim 1 wherein R^5 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein R^{12} is $-N^+(O^-)NR^{13}R^{14}$ or $-N(OH)R^{13}$ wherein R^{13} and R^{14} are independently selected from the group consisting of unsubstituted lower alkyl.

15

42. The compound of Claim 1 wherein R^5 is 2-(N-hydroxy-N-ethylamino)ethylaminocarbonyl or 2-[$N^+(O^-)(C_2H_5)_2$]ethylaminocarbonyl

20

43. The compound of Claim 1 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein R^{12} is $-N^+(O^-)NR^{13}R^{14}$ or $-N(OH)R^{13}$ wherein R^{13} and R^{14} are independently selected from the group consisting of unsubstituted lower alkyl.

25

44. The compound of Claim 1 wherein R^6 is 2-(N-hydroxy-N-ethylamino)ethylaminocarbonyl or 2-[$N^+(O^-)(C_2H_5)_2$]ethylaminocarbonyl.

30

45. The compound or salt of Claim 37, 38, 41 or 42 wherein:
 R^6 is selected from the group consisting of hydrogen, or methyl; and
 R^7 is selected from the group consisting of methyl, hydrogen or phenyl.

35

46. The compound or salt of any of the Claims 39, 40, 43, 44 or 20-22 wherein:

R⁵ is selected from the group consisting of hydrogen, or methyl; and

R⁷ is selected from the group consisting of methyl, hydrogen or phenyl.

5

47. The compound or salt of Claim 45 wherein:

R¹ is hydrogen;

R² is hydrogen, cyano, chloro, fluoro, or bromo;

R³ is hydrogen; and

10

R⁴ is hydrogen.

48. The compound or salt of Claim 46 wherein:


R¹ is hydrogen;

R² is cyano, chloro, fluoro, or bromo;

R³ is hydrogen; and

R⁴ is hydrogen.

49. The compound or salt of Claim 1, wherein the compound is selected from the group consisting of:



20

or an L-malate salt thereof.

50. A pharmaceutical composition, comprising a compound or salt of Claim 1 and, a pharmaceutically acceptable carrier or excipient.

5 51. A pharmaceutical composition, comprising a compound or salt of Claim 49 and, a pharmaceutically acceptable carrier or excipient.

10 52. A method for the modulation of the catalytic activity of a protein kinase comprising contacting said protein kinase with a compound or salt of Claim 1 or 49.

15 53. The method of Claim 52 wherein said protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.

20 54. A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound or salt of Claim 50 or Claim 51 and, a pharmaceutically acceptable carrier or excipient to said organism.


25 55. The method of Claim 54 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

30 56. The method of Claim 54 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

35 57. The method of Claim 54 wherein said protein kinase

related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

- 5 58. The method of Claim m 54 wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.
- 10 59. The method of Claim 54 wherein said organism is a human.
- 15 60. An intermediate of Formula (II):



(II)

- 25 wherein:
- R⁵ is selected from the group consisting of hydrogen, alkyl and -C(O)R¹⁰;
- R⁶ is selected from the group consisting of hydrogen, alkyl and -C(O)R¹⁰;
- 30 R⁷ is selected from the group consisting of hydrogen,

alkyl, aryl, heteroaryl, $-C(O)R^{17}$ and $-C(O)R^{10}$;

R⁶ and R⁷ may combine to form a group selected from the group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$ and $-(CH_2)_6-$;
with the proviso that at least one of R⁵, R⁶ or R⁷ must be
5 $-C(O)R^{10}$;

R¹⁰ is selected from the group consisting of hydroxy,
alkoxy, aryloxy, $-N(R^{11})(CH_2)_nR^{12}$ and $-NR^{13}R^{14}$;

R¹¹ is selected from the group consisting of hydrogen and
alkyl;

10 R¹² is selected from the group consisting of $-NR^{13}R^{14}$,
hydroxy, $-C(O)R^{15}$, aryl and heteroaryl;

R¹³ and R¹⁴ are independently selected from the group
consisting of hydrogen, alkyl, cyanoalkyl, cycloalkyl, aryl
and heteroaryl; or

15 R¹³ and R¹⁴ may combine to form a heterocyclo group;

R¹⁵ is selected from the group consisting of hydrogen,
hydroxy, alkoxy and aryloxy;

R¹⁷ is selected from the group consisting of alkyl,
cycloalkyl, aryl and heteroaryl; and
20 n is 1, 2, 3, or 4.